HIV Clinical Trial
— LSPYOfficial title:
Life Steps for PrEP for Youth
Verified date | March 2023 |
Source | Fenway Community Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a formative study, designed to provide information required to tailor Life-Steps for Pre-Exposure Prophylaxis (PrEP), an evidence-based cognitive behavioral adherence intervention, to enhance PrEP uptake and adherence in high risk young men who have sex with men (YMSM) and young transgender women who have sex with men (YTWSM). Life-Steps for Pre-exposure prophylaxis (PrEP) is a manualized modular adherence intervention based on principles of cognitive-behavioral therapy (CBT), that allows for recipients of the intervention to focus on the greatest challenges that they perceive in maintaining optimal adherence to PrEP.
Status | Completed |
Enrollment | 32 |
Est. completion date | November 15, 2022 |
Est. primary completion date | May 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 16 Years to 24 Years |
Eligibility | Inclusion Criteria: - age 16-24 - HIV-uninfected by self-report - Assigned male sex at birth - self-identify as a man who has sex with men or a trans woman who has sex with men - able to understand English Self-reported HIV risk is defined as meeting at least one of the following criteria: - At least one episode of unprotected anal intercourse with an HIV-positive partner with a penis or a partner with a penis of unknown HIV status during the last 6 months; - Anal intercourse with 3 or more partners with a penis during the last 6 months; - Exchange of money, gifts, shelter or drugs for anal sex with a partner with a penis during the last 6 months; - Sex with a partner with a penis and has had an STI(sexually transmitted infection) during the last 6 months; - Sexual partner of an HIV-positive person with a penis with whom condoms were not consistently used in the last 6 months; or - At least one episode of anal intercourse where the condom broke or slipped off during the last 6 months Exclusion Criteria: - Currently enrolled in another PrEP adherence study* - Prior enrollment in an HIV vaccine trial with receipt of experimental vaccine product.* - Enrollment in earlier phase of Life Steps for PrEP for Youth* - Unable to give informed consent/assent due to severe mental or physical illness/substance intoxication at baseline visit - Has severe cognitive limitation that would limit their ability to comprehend the informed consent or assent - Presence of an active (i.e. untreated) and interfering psychiatric disorder (e.g., bipolar disorder, schizophrenia, substance abuse) |
Country | Name | City | State |
---|---|---|---|
United States | PRISM Health | Atlanta | Georgia |
United States | Fenway Health | Boston | Massachusetts |
United States | Core Center | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Fenway Community Health | Brown University, Cook County Hospital, Emory University, Massachusetts General Hospital, University of North Carolina |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adapt Life-Steps for PrEP to be appropriate for at-risk young men who have sex with men (YMSM) and young transgender women who have sex with men (YTWSM) | Study Investigators will conduct qualitative interviews with up to 20 HIV-uninfected YMSM/TWSM at Fenway Health and with up to 10 key informants, including PrEP providers and staff at community-based organizations that work with YMSM/TWSM. Interviews will be transcribed and analyzed using content analysis to identify changes that should be made to the Life-Steps intervention. | one time qualitative interviews will be conducted | |
Primary | Pre-Exposure Prophylaxis (PrEP) Adherence at 3 months post PrEP initiation | Measured by dried blood spot (DBS) testing of tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) | Blood sample collected at 3 month visit post baseline | |
Primary | Pre-Exposure Prophylaxis (PrEP) Adherence at 6 months post PrEP initiation | Measured by dried blood spot (DBS) testing of tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) | blood sample collected at 6 month visit post baseline | |
Secondary | Retention in Pre-Exposure Prophylaxis (PrEP) care and prevention services | Attendance at quarterly clinic appointments obtained through medical record abstraction | Records will be abstracted at the end of the study period for each participant to determine if they attended a clinic appointment at 3 and 6 months post baseline | |
Secondary | LifeSteps for PrEP for Youth Intervention Acceptability | To measure acceptability, participants will be asked to self-report the degree to which they find the intervention appropriate and useful using Likert-type agreement scales. | Measured at each study visit (3 and 6 months post baseline) | |
Secondary | LifeSteps for PrEP for Youth Intervention Satisfaction | Satisfaction will be measured with the Client Satisfaction Questionnaire (CSQ-8). The CSQ-8 is an 8-item, easily scored and administered measurement designed to measure client satisfaction with services.
The CSQ-8 has been extensively studied, and while it is not necessarily a measure of a client's perceptions of gain from treatment, or outcome, it does elicit the client's perspective on the value of services received. The CSQ-8 seems to operate about the same across all ethnic groups. The CSQ-8 is scored by summing the item scores to produce a range of 8 to 32, with high scores indicating greater satisfaction. Larsen, D.L., Attkisson, C.C., Hargreaves, W.A., and Nguyen, T.D. (1979). Assessment of client/patient satisfaction: Development of a general scale, Evaluation and Program Planning, 2, 197-207. Instrument reproduced with permission of C. Clifford Attkisson. Attkisson, C. C., & Greenfield, T. K. (1994). Client Satisfaction Questionnaire-8 and Service Satisfaction Scale-30. |
Measured at each study visit (3 and 6 months post baseline) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 | |
Completed |
NCT03477279 -
Developing and Assessing a Male Engagement Intervention in Option B+ in Malawi
|
N/A |